Determination of an oxadiazole-substituted 1,4-benzodiazepine in plasma by high-performance liquid chromatography with ultraviolet detection and by a radioreceptor assay.
A high-performance liquid chromatographic (HPLC) method for the determination of an oxadiazole-substituted 1,4-benzodiazepine [3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5,6-dihydro-5-methyl-6-oxo -4H-imidazo[1,5a] [1,4]benzodiazepine] in plasma has been developed and compared with a radioreceptor assay. The results given by the two methods were in good agreement, with detection limits of ca. 1 ng/ml (signal-to-noise ratio = 3). The radioreceptor method is preferred for the monitoring of toxicological and other well controlled studies, while HPLC is preferred where greater specificity is essential. Further, the HPLC assay is applicable over a much wider concentration range.
Nordholm
L
L
Department of Drug Metabolism, Ferrosan Research Division, Soeborg, Denmark.
Mengel
H
H
D000818:Animals; D014151:Anti-Anxiety Agents / Q000097:blood*; D001569:Benzodiazepines / Q000097:blood*; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D004347:Drug Interactions; D000882:Haplorhini / Q000097:blood; D006801:Humans; D011869:Radioligand Assay; D051381:Rats / Q000097:blood; D013056:Spectrophotometry, Ultraviolet
D014151:Anti-Anxiety Agents; C061856:FG 8119; D001569:Benzodiazepines